Vimarsana
Biggest News Aggregation in the World

Page 40 - Confidence Interval News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Confidence Interval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Confidence Interval Today - Breaking & Trending Today

Study Examines Prevalence, Drivers of Racial Disparities in T2D Following Gestational Diabetes - Vimarsana News

Study Examines Prevalence, Drivers of Racial Disparities in T2D Following Gestational Diabetes

An analysis of data from more than 20,000 women in the New York City A1c registry details the prevalence of and drivers behind racial/ethnic disparities in the incidence of type 2 diabetes following gestational diabetes mellitus.

Interim Effectiveness Estimates of 2023 Southern Hemisphere Influenza Vaccines in Preventing Influenza-Associated Hospitalizations — REVELAC-i Network, March–July 2023 - Vimarsana News

Interim Effectiveness Estimates of 2023 Southern Hemisphere Influenza Vaccines in Preventing Influenza-Associated Hospitalizations — REVELAC-i Network, March–July 2023

This report describes flu vaccine effectiveness data from five South American countries during the 2023 Southern Hemisphere flu season.

Source: cdc.gov
Low-dose glucocorticoids for rheumatoid arthritis do not increase blood pressure - Vimarsana News

Low-dose glucocorticoids for rheumatoid arthritis do not increase blood pressure

1. In this pooled analysis of randomized controlled trials, low-dose glucocorticoids taken over a two-year period did not increase patient blood pressure. 2. Low-dose glucocorticoid use was associated with an increase in weight of one kilogram on average. Evidence Rating Level: 1 (Excellent) Study Rundown: Glucocorticoids are commonly used in the management of rheumatoid arthritis

Pitavastatin reduces cardiovascular event risk among patients with HIV - Vimarsana News

Pitavastatin reduces cardiovascular event risk among patients with HIV

1. In this randomized controlled trial, among patients living with human immunodeficiency virus (HIV) at low-to-moderate risk of cardiovascular disease, pitavastatin calcium was superior to placebo in reducing the risk of a major adverse cardiovascular event (MACE). 2. The trial was stopped early due to evidence of the efficacy and safety of pitavastatin. Evidence Rating

Orexin receptor 2 agonist reduces symptoms of narcolepsy type 1 - Vimarsana News

Orexin receptor 2 agonist reduces symptoms of narcolepsy type 1

1. In this randomized controlled trial, an oral orexin receptor 2 (OX2R) agonist (TAK-994) was associated with improvements in wakefulness, sleepiness, and cataplexy incidence among patients with narcolepsy type 1. 2. TAK-994 was also associated with liver enzyme elevation and drug-induced hepatotoxicity. Evidence Rating Level: 1 (Excellent) Study Rundown: Narcolepsy is a rare chronic disorder